Bull
$2.24
シナリオ価格
$3.000
-0.399 (-13.29%)終値時点
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.
Given the current price of $3.00 and an RSI of 23.016, which indicates that the stock is oversold, SXTC does not present a good buying opportunity right now. The stock has experienced a staggering 99.99% decline year-to-date, reflecting severe underlying issues. Additionally, the recent reverse stock split and subsequent price drop of nearly 30% raise significant concerns about the company's stability and future prospects.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

China SXT Pharmaceuticals Closes $9 Million Direct Offering

China SXT Pharmaceuticals Secures $9M Direct Offering

DarkIris Inc Reports 27.3% Revenue Growth, Shares Surge

China SXT Pharmaceuticals Announces 1-for-150 Reverse Stock Split to Boost Share Price

China SXT Pharmaceuticals Announces 1-for-150 Share Consolidation
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Given the current price of $3.00 and an RSI of 23.016, which indicates that the stock is oversold, SXTC does not present a good buying opportunity right now. The stock has experienced a staggering 99.99% decline year-to-date, reflecting severe underlying issues. Additionally, the recent reverse stock split and subsequent price drop of nearly 30% raise significant concerns about the company's stability and future prospects.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。